Back

Chromatin remodeling by the histone methyltransferase SETD2 drives cardiometabolic heart failure with preserved ejection fraction

1 September 2024 (09:50 - 10:00)
Organised by: Logo
Congress Presentation Part of: Epigenetic targets in cardiovascular disease Heart Failure ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Sarah Costantino

University Hospital Zurich, Zurich (Switzerland)

5 More presentations in this session

Presentation thumbnail
Targeting BRD4-HK2 reverses the meta-inflammatory shift in perivascular adipose tissue and rescues cardiometabolic vascular dysfunction.
Assistant Professor A. Mengozzi (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Targeting the histone methyltransferase SETD7 rescues diabetes-induced impairment of angiogenic response by transcriptional repression of semaphorin 3G
Doctor S. Mohammed (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Epigenetic BET inhibitor apabetalone counters inflammatory and fibrotic processes in activated cardiac fibroblasts providing insight into reduced hospitalizations for heart failure in BETonMACE trial
Doctor E. Kulikowski (Calgary, CA)
Abstract Slides Video
Presentation thumbnail
The BET inhibitor Apabetalone protects against heart failure with preserved ejection fraction by suppressing myocardial inflammation
Doctor E. Gorica (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
RBM20 promotes doxorubicin-induced cardiotoxicity by Atp6v0a1 alternative splicing
Doctor Z. Qiu (Shanghai, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Epigenetic targets in cardiovascular disease
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 09:50 CET
You may be interested in
thumbnail
Congress Presentation
Adverse chromatin remodelling by SETD7 drives inflammation and diastolic dysfunction in obese heart failure with preserved ejection fraction
thumbnail
Congress Presentation
The histone methyltransferase SETD2 promotes lipotoxic injury in cardiometabolic heart failure with preserved ejection fraction
thumbnail
Congress Presentation
Chromatin-editing drugs in heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources